ClinicalTrials.gg
CompletedNCT04583995Updated May 8, 2025

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

A Phase 3 interventional study of SARS-CoV-2 rS/Matrix M1-Adjuvant and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by Novavax. Completed at 33 sites in United Kingdom. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by Novavax · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15,185
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
2nd of 18
15,185 · median 997
Started
2020
with 3 others
Phase 3
7 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 2nd largest by enrollment, is one of 4 that started in 2020, is one of 7 in phase 3, and was the 3rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom. A vaccine causes the body to have an immune response that may help prevent the infection or reduce the severity of symptoms. An adjuvant is something that can make a vaccine work better. This study will look at the protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1 adjuvant in the study population. Participants in the study will randomly be assigned to receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will receive a total of 2 intramuscular injections over the course of the study. Approximately 15,000 participants will take part in the study. The first approximately 400 participants who meet additional criteria will receive a flu vaccine, in addition to the SARS-CoV-2 rS vaccine or placebo, as part of a sub-study.

An effort will be made to enroll a target of at least 25% of participants who are ≥ 65 years of age, as well as prioritizing other groups that are most affected by COVID-19, including racial and ethnic minorities.

Unblinding of treatment assignment may occur in order to allow a participant to make an informed decision regarding receipt of an already approved or deployed SARS-CoV-2 vaccine. Participants who choose to receive an approved or deployed SARS-CoV-2 vaccine as per UK government guidance will be encouraged to remain in the study for scheduled safety assessments.

03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • Coronavirus
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to comply with all study requirements.
  • Willing to allow investigators to discuss medical history with their General Practitioner and access all relevant medical records.
  • Willing and able to give .
  • Women of must agree not to have sexual intercourse with men, or must consistently use an agreed method of , from at least 28 days prior to enrolment in the study, through 3 months after the last vaccination.
  • Room air oxygen saturation > 95% at Screening/Day 0.
  • Seasonal Flu Vaccine Co-Administration Sub-Study only: Participant should not have received a current season flu vaccine, should have no reason why the specific sub-study flu vaccine cannot be administered, and should not have any prior history of allergy or severe reaction to seasonal flu vaccines.

Exclusion criteria

Exclusion Criteria:

  • Participation in other COVID-19 vaccine or preventative drug trials for the duration of the study.
  • Future participation in any blood tests for the duration of the study where participants are informed of their levels of COVID-19 antibodies or antigens.
  • Participation in any trial involving an drug, biologic or device within 45 days prior to the first study vaccination.
  • History of laboratory-confirmed COVID-19 infection any time prior to first study vaccination.
  • Receipt of any immunoglobulins and/or any blood products within 3 months prior to planned administration of study vaccine.
  • Any confirmed or suspected or immunodeficient state. Chronic administration (defined as more than 14 continuous days) of immunosuppressant medication within the past 3 months, except topical or short-term oral steroids (course lasting ≤ 14 days). Note: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted if other chronic disease conditions do not exclude a participant from the study.
  • History of allergic disease or reactions likely to be made worse by any component of the study vaccines.
  • History of anaphylaxis to any prior vaccine.
  • Pregnancy, breast-feeding or willingness/intention to become pregnant within 3 months following the last study vaccination.
  • Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ.
  • Bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venepuncture (e.g. to draw blood for tests).
  • Continuous use of anticoagulants or anti- agents. Note: The preventative use of ≤ 325 mg of aspirin per day is permitted.
  • Suspected or known current alcohol or drug dependency.
  • Study team member or first-degree relative of any study team member (inclusive of sponsor, contract research organization (CRO), and site personnel involved in the study).
  • Participants having any current workup of undiagnosed illness within 8 weeks prior to start of study which could lead to new condition or diagnosis.
  • Received any within 4 weeks or any vaccine (excluding flu) within 2 weeks prior to first study vaccination; or any licensed flu vaccine within 1 week prior to first study vaccination or plans to receive any vaccine from these time periods until 28 days after the second study vaccination.
  • Have chronic cardiovascular, endocrine (hormones), gastrointestinal, hepatic (including and C), renal (kidney), neurological, respiratory, psychiatric or other medical disorders not excluded by other exclusion criteria, that are assessed by the investigator as being clinically unstable within the prior 4 weeks as evidenced by: a) Hospitalisation for the condition, including day surgical interventions; b) New significant organ function deterioration; or c) Needing addition of new treatments or major dose adjustments of current treatments (mild or moderate well-controlled comorbidities are allowed).
  • History of chronic neurological disorders that have required prior specialist physician review for diagnosis and management (such as multiple sclerosis, dementia, , Parkinson's disease, degenerative neurological conditions, and neuropathy) or a history of stroke or previous neurological disorder within 12 months with residual symptoms. Participants with a history of migraine or chronic headaches or nerve root compression that have been stable on treatment for the last 4 weeks are not excluded.
  • Any disease/condition (iatrogenic or congenital).
  • Any other significant disease, disorder or finding that, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study, or impair interpretation of the study data.
  • Participant requires the use of continuous oxygen therapy or any oxygen therapy while awake or is anticipated to require daytime oxygen therapy during the course of the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15,185 participants (actual)

Study arms

  • Experimental
    Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant

    2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.

    Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant

  • Placebo comparator
    Cohort 1: Placebo

    2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.

    Other: Placebo

  • Experimental
    Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine

    2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.

    Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant · Biological: Licensed seasonal influenza vaccine

  • Placebo comparator
    Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine

    2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.

    Other: Placebo · Biological: Licensed seasonal influenza vaccine

Interventions

  • BiologicalSARS-CoV-2 rS/Matrix M1-Adjuvant

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.

    Also known as: NVX-CoV2373

  • OtherPlacebo

    Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.

    Also known as: Sodium chloride 0.9% (BP, sterile)

  • BiologicalLicensed seasonal influenza vaccine

    Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0.

06

What researchers measure

Primary outcomes

  1. Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)

    Number of participants, testing serologically negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline, with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 with onset from Day 28 through the length of the study.

    Time frame: From Day 28 to Day 386

Secondary outcomes

  1. Participants with Symptomatic Moderate or Severe COVID-19

    Number of participants, testing serologically negative for SARS-CoV-2 at baseline with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic moderate or severe COVID-19 with onset from Day 28 through the length of the study.

    Time frame: From Day 28 to Day 386

  2. Participants with Symptomatic Severe COVID-19

    Number of participants, testing serologically negative for SARS-CoV-2 at baseline with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic severe COVID-19 with onset from Day 28 through the length of the study.

    Time frame: From Day 28 to Day 386

  3. Participants with Symptomatic Mild, Moderate, or Severe COVID-19 Regardless of Baseline Serostatus

    Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 assessed from Day 28 through the length of the study.

    Time frame: From Day 28 to Day 386

  4. Participants with Asymptomatic or Symptomatic COVID-19

    Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, or nucleocapsid protein serologically confirmed, SARS-CoV-2 illness with asymptomatic or symptomatic COVID-19 with onset from Day 28 through the length of the study.

    Time frame: From Day 28 to Day 386

  5. Participants with COVID-19 requiring Hospitalization, Intensive Care Unit (ICU), or Mechanical Ventilation

    Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with COVID-19 with onset from Day 28 through the length of the study.

    Time frame: From Day 28 to Day 386

  6. Participants with Symptomatic Mild COVID-19

    Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild COVID-19 (with no progression to moderate or severe COVID-19 during the course of the COVID-19 episode) with onset from Day 28 through the length of the study.

    Time frame: From Day 28 to Day 386

  7. Serum IgG Antibody Levels at Multiple Time Points Expressed as Geometric Mean ELISA Units (GMEUs)

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMEUs at Day 0 and Day 35.

    Time frame: Day 0 to Day 35

  8. Participants with Serious Adverse Events (SAEs)

    Number of participants with SAEs through the length of the study by Medical Dictionary for Regulatory Activities (MedDRA) classification and relationship to study vaccination.

    Time frame: 386 days

  9. Participants with Medically Attended Adverse Events (MAAEs) Related to Study Vaccination

    Number of participants with MAAEs related to study vaccination through the length of the study by MedDRA classification.

    Time frame: 386 days

  10. Participants with Adverse Events of Special Interest (AESIs)

    Number of participants with AESIs, which include potential immune-mediated medical conditions (PIMMCs) and AESIs relevant to COVID-19 such as possible vaccine-enhanced disease by MedDRA classification through the length of the study.

    Time frame: 386 days

  11. Participants with Solicited Local and Systemic Adverse Events (AEs)

    Number of participants with solicited local and systemic AEs for 7 days after each study vaccination.

    Time frame: 28 days

  12. Participants with All MAAEs Through Day 35

    Number of participants with all MAAEs through Day 35 by MedDRA classification and relationship to study vaccination.

    Time frame: 35 days

  13. Participants with Unsolicited AEs Through Day 49

    Number of participants with unsolicited AEs through Day 49 by MedDRA classification and relationship to study vaccination.

    Time frame: 49 days

07

Study locations

33 sites
  • Belfast Health and Social Care Trust (BHSCT) (Site UK011)
    Belfast, Antrim BT9 7AB, United Kingdom
  • Synexus Midlands Clinical Research Centre (Site UK024)
    Edgbaston, Birmingham B15 2 SQ, United Kingdom
  • The Royal Cornwall Hospitals NHS Trust (Site UK036)
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Royal Devon and Exeter Hospital (Site UK013)
    Exeter, Devon EX2 5DW, United Kingdom
  • "Maidstone Hospital - Central Research and Development Office Above Breast Care Centre - 1st Floor" (Site UK028)
    Maidstone, Kent ME16 9QQ, United Kingdom
  • Queen Elizabeth University Hospital (Site UK008)
    Glasgow, Lanarkshire G51 4TF, United Kingdom
  • Blackpool Teaching Hospitals (Site UK010)
    Blackpool, Lancashire FY3 8NR, United Kingdom
  • Salford Hospital (Site UK030)
    Oldham, Lancashire OL1 2JH, United Kingdom
  • Synexus Merseyside Clinical Research Centre (Site UK026)
    Waterloo, Liverpool L22 0LG, United Kingdom
  • Royal Free (Site UK012)
    Hampstead, London NW3 2QG, United Kingdom
  • St. George's University Hospitals NHS Foundation Trust Clinical Research Facility (Site UK001)
    Tooting, London SW17 0QT, United Kingdom
  • North Wales Clinical Research Centre (NWCRC) (Site UK027)
    Wrexham, North Wales LL13 7YP, United Kingdom
  • Lakeside Healthcare, Lakeside Surgery (Site UK005)
    Corby, Northants NN17 2UR, United Kingdom
  • Warneford Hospital (Site UK016)
    Oxford, Oxfordshire OX3 7JX, United Kingdom
  • Aberdeen Royal Infirmary (Site UK007), Foresterhill
    Aberdeen, AB25 2ZN, United Kingdom
  • Bradford Teaching Hospitals NHS Trust (Site UK018)
    Bradford, BD9 6RJ, United Kingdom
  • Synexus Wales Clinical Research Centre (Site UK025)
    Cardiff, CF15 9SS, United Kingdom
  • Synexus Lancashire Clinical Research Centre (Site UK022)
    Chorley, PR7 7 NA, United Kingdom
  • Colchester Hospital (Site UK034)
    Colchester, CO4 5JL, United Kingdom
  • AES - Glasgow (Site UK033)
    Glasgow, G20 0SP, United Kingdom
  • University Hartlepool Hospital (Site UK021)
    Hartlepool, TS24 9AH, United Kingdom
  • Synexus Hexham Clinical Research Centre (Site UK023)
    Hexham, NE46 1QJ, United Kingdom
  • Royal Lancaster Infirmary (Site UK029)
    Lancaster, LA1 4RP, United Kingdom
  • Research & Innovation Centre, St. James's University Hospital (Site UK019)
    Leeds, LS9 7TF, United Kingdom
  • St. Thomas' Hospital (Site UK020)
    London, SE1 7EH, United Kingdom
  • Chelsea & Westminster NHS Foundation Trust (Site UK006)
    London, SW10 9NH, United Kingdom
  • AES - Synexus Manchester (Site UK032)
    Manchester, M15 6SE, United Kingdom
  • Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk and Norwich University Hospital (Site UK015)
    Norwich, NR4 7UY, United Kingdom
  • Wansford and Kingscliffe Practice (Site UK035)
    Peterborough, PE8 6PL, United Kingdom
  • AES - Synexus Thames Valley (Site UK031)
    Reading, RG2 0TG, United Kingdom
  • University Hospital Southampton NHS Foundation Trust (UHS) (Site UK014)
    Southampton, SO16 6YD, United Kingdom
  • Midlands Partnership NHS Foundation Trust Headquarters (Site UK017)
    Stafford, ST16 3SR, United Kingdom
  • Stockport NHS Foundation Trust (Site UK009)
    Stockport, SK2 7JE, United Kingdom
08

References and documents

Publications

  • Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, Rajaram S, Graves-Jones A, Edelman J, Burns F, Minassian AM, Cho I, Kumar L, Plested JS, Rivers EJ, Robertson A, Dubovsky F, Glenn G, Heath PT; 2019nCoV-302 Study Group. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Feb;10(2):167-179. doi: 10.1016/S2213-2600(21)00409-4. Epub 2021 Nov 17. PubMed 34800364 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Mar 2022, 18 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 18 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2020
First posted
Oct 12, 2020
StartActual
Sep 28, 2020
Primary completionActual
Mar 29, 2022
CompletionActual
Mar 29, 2022
Results delay requested
Mar 28, 2023
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04583995
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
Oct 12, 2020
Start date
Sep 28, 2020
Primary completion
Mar 29, 2022
Completion
Mar 29, 2022
Last update
May 8, 2025

Study contacts

Clinical Development
study director · Novavax, Inc.
Paul T Heath, MB BS FRACP FRCPCH
principal investigator · Vaccine Institute, St Georges, University of London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion